IPAD: the Integrated Pathway Analysis Database for Systematic Enrichment Analysis.

Authors:
Fan Zhang
Fan Zhang
School of Pharmacy
Madison | United States
Renee Drabier
Renee Drabier
University of North Texas Health Science Center

BMC Bioinformatics 2012 11;13 Suppl 15:S7. Epub 2012 Sep 11.

Department of Academic and Institutional Resources and Technology, University of North Texas Health Science Center, Fort Worth, USA.

Background: Next-Generation Sequencing (NGS) technologies and Genome-Wide Association Studies (GWAS) generate millions of reads and hundreds of datasets, and there is an urgent need for a better way to accurately interpret and distill such large amounts of data. Extensive pathway and network analysis allow for the discovery of highly significant pathways from a set of disease vs. healthy samples in the NGS and GWAS. Knowledge of activation of these processes will lead to elucidation of the complex biological pathways affected by drug treatment, to patient stratification studies of new and existing drug treatments, and to understanding the underlying anti-cancer drug effects. There are approximately 141 biological human pathway resources as of Jan 2012 according to the Pathguide database. However, most currently available resources do not contain disease, drug or organ specificity information such as disease-pathway, drug-pathway, and organ-pathway associations. Systematically integrating pathway, disease, drug and organ specificity together becomes increasingly crucial for understanding the interrelationships between signaling, metabolic and regulatory pathway, drug action, disease susceptibility, and organ specificity from high-throughput omics data (genomics, transcriptomics, proteomics and metabolomics).

Results: We designed the Integrated Pathway Analysis Database for Systematic Enrichment Analysis (IPAD, http://bioinfo.hsc.unt.edu/ipad), defining inter-association between pathway, disease, drug and organ specificity, based on six criteria: 1) comprehensive pathway coverage; 2) gene/protein to pathway/disease/drug/organ association; 3) inter-association between pathway, disease, drug, and organ; 4) multiple and quantitative measurement of enrichment and inter-association; 5) assessment of enrichment and inter-association analysis with the context of the existing biological knowledge and a "gold standard" constructed from reputable and reliable sources; and 6) cross-linking of multiple available data sources.IPAD is a comprehensive database covering about 22,498 genes, 25,469 proteins, 1956 pathways, 6704 diseases, 5615 drugs, and 52 organs integrated from databases including the BioCarta, KEGG, NCI-Nature curated, Reactome, CTD, PharmGKB, DrugBank, PharmGKB, and HOMER. The database has a web-based user interface that allows users to perform enrichment analysis from genes/proteins/molecules and inter-association analysis from a pathway, disease, drug, and organ.Moreover, the quality of the database was validated with the context of the existing biological knowledge and a "gold standard" constructed from reputable and reliable sources. Two case studies were also presented to demonstrate: 1) self-validation of enrichment analysis and inter-association analysis on brain-specific markers, and 2) identification of previously undiscovered components by the enrichment analysis from a prostate cancer study.

Conclusions: IPAD is a new resource for analyzing, identifying, and validating pathway, disease, drug, organ specificity and their inter-associations. The statistical method we developed for enrichment and similarity measurement and the two criteria we described for setting the threshold parameters can be extended to other enrichment applications. Enriched pathways, diseases, drugs, organs and their inter-associations can be searched, displayed, and downloaded from our online user interface. The current IPAD database can help users address a wide range of biological pathway related, disease susceptibility related, drug target related and organ specificity related questions in human disease studies.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2105-13-S15-S7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439721PMC

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
April 2013
64 Reads

Publication Analysis

Top Keywords

disease drug
24
organ specificity
24
pathway disease
24
drug organ
20
enrichment analysis
20
inter-association analysis
12
pathway
12
analysis
11
drug
11
disease
10
enrichment
9
standard" constructed
8
"gold standard"
8
constructed reputable
8
drugs organs
8
reputable reliable
8
knowledge "gold
8
enrichment inter-association
8
inter-association pathway
8
disease susceptibility
8

References

(Supplied by CrossRef)

Similar Publications

"Scratches/Abrasions without Bleeding" Cause Rabies: A 7 Years Rabies Death Review from Medical College Shimla, Himachal Pradesh, India.

Indian J Community Med 2017 Oct-Dec;42(4):248-249

State Correspondent, The Statesman and Alumni of HP Agriculture University, Palampur, Himachal Pradesh, India.

View Article
November 2017
11 Reads

Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.

Am J Clin Pathol 2016 Jul 27;146(1):78-85. Epub 2016 Jun 27.

From the National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom

Objectives: Measurement of serum free light chains (FLCs) is critical in diagnosis, prognosis, and monitoring treatment responses in light chain (AL) amyloidosis. We compare the Freelite assay (polyclonal antibodies to hidden light chain epitopes), which is the current gold standard, with a new assay: a mixture of monoclonal antibodies to light chain epitopes (N Latex).

Methods: We collected 240 serum samples from 94 consecutive patients with newly diagnosed AL amyloidosis (at least three serial serum samples during the first 6 months) analyzed at the National Amyloidosis Centre, London, from January 2011 to April 2012. Read More

View Article
July 2016
12 Reads
2.51 Impact Factor

Fanconi-Bickel syndrome versus osteogenesis imperfeeta: An Iranian case with a novel mutation in glucose transporter 2 gene, and review of literature.

Indian J Hum Genet 2013 Jan;19(1):84-6

Department of Medical Genetics, Sarem Cell Research Center, Sarem Women Hospital, Tehran, Iran.

Fanconi-Bickel syndrome is an extremely rare hereditary metabolic disease, characterized by hepatomegaly due to glycogen storage, refractory hypophosphatemic rickets, marked growth retardation and proximal renal tubular acidosis. Recurrent bone fractures are one of the hallmark findings. It is a single gene disorder; the responsible gene belongs to the facilitative glucose transporters 2 (GLUT2) family gene or (SLC2A2) mapped to the q26. Read More

View Article
January 2013
10 Reads
1 PubMed Central Citation(source)

A rare and particular form of goiter to recognize.

Ann Transl Med 2013 Jul;1(2):21

1 Department of Pathology, 2 Department of Thoracic Surgery, Abderrahmen Mami Hospital, 2083 Ariana, Tunisia.

Dyshormonogenetic goiter is a rare cause of congenital hypothyroidism occurring due to a lack of enzymes necessary for the synthesis of thyroid hormones. It is morphologically characterized by architectural and cellular pleomorphism that may mimic thyroid malignancy and cause difficulties in differential diagnosis. We report a new case occurring in a 37-year-old male with history of hypothyroidism since the age of 
6 years treated by L-thyroxin. Read More

View Article
July 2013
20 Reads

Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy.

J Infect Dis 2013 Oct 6;208(7):1113-22. Epub 2013 Jun 6.

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston MA 02215, USA.

Background: Human immunodeficiency virus type 1 (HIV-1) infection is associated with a massive depletion of intestinal CD4(+) T cells that is only partially reversed by combination antiretroviral therapy (cART). Here, we assessed the ability of nucleoside reverse-transcriptase inhibitor/nonnucleoside reverse-transcriptase inhibitor treatment to restore the CD4(+) T-cell populations in the intestine of South African patients with AIDS.

Methods: Thirty-eight patients with advanced HIV-1 infection who had chronic diarrhea (duration, >4 weeks) and/or unintentional weight loss (>10% decrease from baseline) of uncertain etiology were enrolled. Read More

View Article
October 2013
21 Reads
7 PubMed Central Citations(source)
6.00 Impact Factor